{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:35Z","timestamp":1791993935384,"version":"4.4.0"},"reference-count":73,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Anderson-Fabry disease (FD) is an X-linked lysosomal storage disorder leading to a wide array of clinical manifestations. Among these, gastrointestinal (GI) symptoms such as abdominal pain, bloating, and diarrhea affect about half of the FD adults and more than half of FD children. GI symptoms could be the first manifestation of FD; however, being non-specific, they overlap with the clinical picture of other conditions, such as irritable bowel syndrome and inflammatory bowel disease. This common overlap is the main reason why FD patients are often unrecognized and diagnosis is delayed for many years. The present narrative review is aimed to promote awareness of the GI manifestations of FD amongst general practitioners and specialists and highlight the latest findings of this rare condition including diagnostic tools and therapies. Finally, we will discuss some preliminary data on a patient presenting with GI symptoms who turned to be affected by a variant of uncertain significance of alpha-galactosidase (GLA) gene.<\/jats:p>","DOI":"10.3390\/ijerph18063320","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T14:08:16Z","timestamp":1616508496000},"page":"3320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Fabio","family":"Caputo","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Department of Internal Medicine, S.S. Annunziata Hospital, Cento (Ferrara), University of Ferrara, 44042 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lungaro","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Department of Internal Medicine, S.S. Annunziata Hospital, Cento (Ferrara), University of Ferrara, 44042 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Galdi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, S.S. Annunziata Hospital, Cento (Ferrara), University of Ferrara, 44042 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Zoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, S.S. Annunziata Hospital, Cento (Ferrara), University of Ferrara, 44042 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Giancola","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences (UNI EN ISO 9001:2008), Alma Mater Studiorum University of Bologna, 40064 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-4529","authenticated-orcid":false,"given":"Giacomo","family":"Caio","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Mucosal Immunology and Biology Research Center, Massachusetts General Hospital-Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-5873","authenticated-orcid":false,"given":"Roberto","family":"De Giorgio","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Zoli","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Department of Internal Medicine, S.S. Annunziata Hospital, Cento (Ferrara), University of Ferrara, 44042 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry Disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wijburg, F.A., B\u00e9nichou, B., Bichet, D.G., Clarke, L.A., Dostalova, G., Fainboim, A., Fellgiebel, A., Forcelini, C., An Haack, K., and Hopkin, R.J. (2015). Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124987"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Namdar, M., Gebhard, C., Studiger, R., Shi, Y., Mocharla, P., Schmied, C., Brugada, P., L\u00fcscher, T.F., and Camici, G.G. (2012). Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease. PLoS ONE, 7.","DOI":"10.1371\/annotation\/7b2c04df-8592-4fb7-8608-3039db28b504"},{"key":"ref_4","first-page":"429","article-title":"Non-Specific Gastrointestinal Features: Could It Be Fabry Disease?","volume":"50","author":"Hilz","year":"2018","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry Disease: Baseline Medical Characteristics of a Cohort of 1765 Males and Females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab Dis"},{"key":"ref_6","first-page":"575","article-title":"Small Fiber Dysfunction Predominates in Fabry Neuropathy","volume":"19","author":"Marthol","year":"2002","journal-title":"J. Clin. Neurophysiol. Off. Publ. Am. Electroencephalogr. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry Disease Frequently Have Major Organ Involvement: Lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry Disease: Progression of Nephropathy, and Prevalence of Cardiac and Cerebrovascular Events before Enzyme Replacement Therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular Involvement in Fabry Disease: Current Status of Knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry Disease: Clinical Manifestations and Impact of Disease in a Cohort of 98 Hemizygous Males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life Expectancy and Cause of Death in Males and Females with Fabry Disease: Findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated Globotriaosylsphingosine Is a Hallmark of Fabry Disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a Consensus in the Laboratory Diagnostics of Fabry Disease\u2014Recommendations of a European Expert Group","volume":"34","author":"Gal","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A Useful Biomarker for the Diagnosis and Treatment of Fabry Disease Heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, Diagnosis, and Management of Patients with Fabry Disease: Conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"key":"ref_16","first-page":"100454","article-title":"The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Male Patients with Fabry Disease: A Systematic Literature Review by a European Panel of Experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme Replacement Therapy for Fabry Disease: Lessons from Two Alpha-Galactosidase A Orphan Products and One FDA Approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme Replacement Therapy for Lysosomal Diseases: Lessons from 20 Years of Experience and Remaining Challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sestito, S., Ceravolo, F., Falvo, F., Nicoletti, A., Stefanelli, E., Apa, R., Salpietro, V., Polizzi, A., Ruggieri, M., and Concolino, D. (2016). Pathobiological Insights into the Newly Targeted Therapies of Lysosomal Storage Disorders. J. Pediatr. Biochem., 6.","DOI":"10.1055\/s-0036-1582224"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107558","DOI":"10.18632\/oncotarget.22505","article-title":"Genetic Variants Associated with Fabry Disease Progression despite Enzyme Replacement Therapy","volume":"8","author":"Scionti","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","first-page":"88","article-title":"Fabry Disease","volume":"12","author":"Thomas","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"110664","DOI":"10.1016\/j.nut.2019.110664","article-title":"Could Nutritional Therapy Take Us Further in Our Approaches to Fabry Disease?","volume":"72","author":"Ravarotto","year":"2020","journal-title":"Nutrition"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry Disease Revisited: Management and Treatment Recommendations for Adult Patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","first-page":"100670","article-title":"Improvement of Gastrointestinal Symptoms in a Significant Proportion of Male Patients with Classic Fabry Disease Treated with Agalsidase Beta: A Fabry Registry Analysis Stratified by Phenotype","volume":"25","author":"Hopkin","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Oder, D., Liu, D., Hu, K., \u00dc\u00e7eyler, N., Salinger, T., M\u00fcntze, J., Lorenz, K., Kandolf, R., Gr\u00f6ne, H.J., and Sommer, C. (2017). \u03b1-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. Circ. Cardiovasc. Genet., 10.","DOI":"10.1161\/CIRCGENETICS.116.001691"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lavalle, L., Thomas, A.S., Beaton, B., Ebrahim, H., Reed, M., Ramaswami, U., Elliott, P., Mehta, A.B., and Hughes, D.A. (2018). Phenotype and Biochemical Heterogeneity in Late Onset Fabry Disease Defined by N215S Mutation. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193550"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Germain, D.P., Brand, E., Burlina, A., Cecchi, F., Garman, S.C., Kempf, J., Laney, D.A., Linhart, A., Mar\u00f3di, L., and Nicholls, K. (2018). Phenotypic Characteristics of the p.Asn215Ser (p.N215S) GLA Mutation in Male and Female Patients with Fabry Disease: A Multicenter Fabry Registry Study. Mol. Genet. Genomic Med.","DOI":"10.1002\/mgg3.389"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a Rare Disease Registry for Establishing Phenotypic Classification of Previously Unassigned GLA Variants: A Consensus Classification System by a Multispecialty Fabry Disease Genotype-Phenotype Workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal Symptoms in 342 Patients with Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural History of Fabry Disease in Females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.2008.00658.x","article-title":"Fabry Disease during Childhood: Clinical Manifestations and Treatment with Agalsidase Alfa","volume":"97","author":"Ramaswami","year":"2008","journal-title":"Acta Paediatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the Gastrointestinal Manifestations of Fabry Disease: Promoting Prompt Diagnosis","volume":"9","author":"Karaa","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The Early Clinical Phenotype of Fabry Disease: A Study on 35 European Children and Adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.2174\/13816128113199990347","article-title":"Gastroenterological Complications of Anderson-Fabry Disease","volume":"19","author":"Buda","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cge.12673","article-title":"Gastrointestinal Involvement in Fabry Disease. So Important, yet Often Neglected","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_38","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/8904_2011_63","article-title":"Gastrointestinal Phenotype of Fabry Disease in a Patient with Pseudoobstruction Syndrome","volume":"4","author":"Buda","year":"2012","journal-title":"JIMD Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0016-5085(84)80028-1","article-title":"Jejunal Diverticulosis with Perforation as a Complication of Fabry\u2019s Disease","volume":"86","author":"Friedman","year":"1984","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/pgmj.67.788.584","article-title":"Colonic Involvement in Fabry\u2019s Disease","volume":"67","author":"Jack","year":"1991","journal-title":"Postgrad Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrg3182","article-title":"The Human Microbiome: At the Interface of Health and Disease","volume":"13","author":"Cho","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00006231-199809000-00009","article-title":"Gastrointestinal Symptoms and Delayed Gastric Emptying in Fabry\u2019s Disease: Response to Metoclopramide","volume":"19","author":"Argoff","year":"1998","journal-title":"Nucl. Med. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","article-title":"Anemia Is a New Complication in Fabry Disease: Data from the Fabry Outcome Survey","volume":"67","author":"Kleinert","year":"2005","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10545-013-9653-8","article-title":"Potential Role of Vitamin D Deficiency on Fabry Cardiomyopathy","volume":"37","author":"Drechsler","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Schuller, Y., Linthorst, G.E., Hollak, C.E.M., Van Schaik, I.N., and Biegstraaten, M. (2016). Pain Management Strategies for Neuropathic Pain in Fabry Disease\u2014A Systematic Review. BMC Neurol., 16.","DOI":"10.1186\/s12883-016-0590-7"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ajg.2016.23","article-title":"Dissecting Molecular Mechanisms in Bile Acid Diarrhea","volume":"111","author":"Camilleri","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85895","DOI":"10.18632\/oncotarget.13135","article-title":"Genetic Variants Associated with Gastrointestinal Symptoms in Fabry Disease","volume":"7","author":"Scionti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0016-5085(82)80262-X","article-title":"Pathophysiologic and Ultrastructural Basis for Intestinal Symptoms in Fabry\u2019s Disease","volume":"82","author":"Shnitka","year":"1982","journal-title":"Gastroenterology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/1047-8477(90)90084-P","article-title":"Glycolipid Storage Material in Fabry\u2019s Disease: A Study by Electron Microscopy, Freeze-Fracture, and Digital Image Analysis","volume":"103","author":"Simon","year":"1990","journal-title":"J. Struct. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00428-008-0653-2","article-title":"Kidney Biopsy Findings in Heterozygous Fabry Disease Females with Early Nephropathy","volume":"453","author":"Valbuena","year":"2008","journal-title":"Virchows Arch."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry Disease: A Review of Current Management Strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Female Patients with Fabry Disease\u2014A Systematic Literature Review by a European Panel of Experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/8904_2017_28","article-title":"Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase Alfa in Pediatric Patients with Fabry Disease: A 6.5-Year Open-Label Follow-up Study","volume":"9","author":"Schiffmann","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00042737-200410000-00020","article-title":"Effect of Enzyme-Replacement Therapy on Gastrointestinal Symptoms in Fabry Disease","volume":"16","author":"Hoffmann","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Burlina, A.P., Sims, K.B., Politei, J.M., Bennett, G.J., Baron, R., Sommer, C., M\u00f8ller, A.T., and Hilz, M.J. (2011). Early Diagnosis of Peripheral Nervous System Involvement in Fabry Disease and Treatment of Neuropathic Pain: The Report of an Expert Panel. BMC Neurol., 11.","DOI":"10.1186\/1471-2377-11-61"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The Management and Treatment of Children with Fabry Disease: A United States-Based Perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lai, H.-H., Chiu, C.-H., Kong, M.-S., Chang, C.-J., and Chen, C.-C. (2019). Probiotic Lactobacillus Casei: Effective for Managing Childhood Diarrhea by Altering Gut Microbiota and Attenuating Fecal Inflammatory Markers. Nutrients, 11.","DOI":"10.3390\/nu11051150"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s12325-019-00924-7","article-title":"Bloating and Abdominal Distension: Clinical Approach and Management","volume":"36","author":"Mari","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ajg.2017.129","article-title":"Bloating and Abdominal Distension: Old Misconceptions and Current Knowledge","volume":"112","author":"Malagelada","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/j.1552-4604.1974.tb01382.x","article-title":"A Double-Blind Trial of Simethicone in Functional Disease of the Upper Gastrointestinal Tract","volume":"14","author":"Bernstein","year":"1974","journal-title":"J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.5009\/gnl13437","article-title":"Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study","volume":"9","author":"Guo","year":"2015","journal-title":"Gut Liver"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.3748\/wjg.v23.i21.3771","article-title":"Diet in Irritable Bowel Syndrome: What to Recommend, Not What to Forbid to Patients!","volume":"23","author":"Loghin","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2013.386","article-title":"Differential Effects of FODMAPs (Fermentable Oligo-, Di-, Mono-Saccharides and Polyols) on Small and Large Intestinal Contents in Healthy Subjects Shown by MRI","volume":"109","author":"Murray","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/gutjnl-2017-313750","article-title":"The Low FODMAP Diet: Recent Advances in Understanding Its Mechanisms and Efficacy in IBS","volume":"66","author":"Staudacher","year":"2017","journal-title":"Gut"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1053\/j.gastro.2020.06.007","article-title":"Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients with Fabry Disease","volume":"159","author":"Lenders","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9712831","DOI":"10.1155\/2016\/9712831","article-title":"Gastrointestinal Symptoms of Patients with Fabry Disease","volume":"2016","author":"Pensabene","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"205948","DOI":"10.1155\/2013\/205948","article-title":"Urine Bikunin as a Marker of Renal Impairment in Fabry\u2019s Disease","volume":"2013","author":"Lepedda","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","article-title":"Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics","volume":"68","author":"Favalli","year":"2016","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/6\/3320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:40:02Z","timestamp":1760161202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/6\/3320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijerph18063320"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18063320","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}